pd-l1 –100% : a rare entity · dr sanju cyriac–medical oncologist, rajagirihospital, india...
TRANSCRIPT
![Page 1: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/1.jpg)
ESMO Preceptorship Programme
PD-L1 – 100% : A rare entity
Dr Sanju Cyriac – Medical Oncologist, Rajagiri Hospital, India
Immuno-oncology– Singapore – 26-27 November 2018
![Page 2: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/2.jpg)
ESMO PRECEPTORSHIP PROGRAMME
� Disclosures: Nil
![Page 3: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/3.jpg)
ESMO PRECEPTORSHIP PROGRAMME
� 64 year old male presented with multiple neck nodes
� Chronic smoker
� Clinically multiple level II- V hard LN palpable
� CT neck and chest: Multiple cervical and mediastinalLN along with right hilar lesion
� Cervical LN biopsy – Adenocarcinoma
� IHC – CK 7+, CK 20 -, TTF +
� PET CT – Multiple cervical and mediastinal lymph nodes, right hilar LN
![Page 4: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/4.jpg)
ESMO PRECEPTORSHIP PROGRAMME
![Page 5: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/5.jpg)
ESMO PRECEPTORSHIP PROGRAMME
� EGFR/ALK mutations: negative
![Page 6: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/6.jpg)
ESMO PRECEPTORSHIP PROGRAMME
� Initiated on Pemetrexed carboplatin
� After 4 cycles – clinicoradiologically excellent
response
� Unfortunately after 4th maintenance Pemetrexed, he
had progression
� He was offered Docetexal vs Nivolumab
� PDL 1 was requested on the initial specimen
![Page 7: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/7.jpg)
ESMO PRECEPTORSHIP PROGRAMME
![Page 8: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/8.jpg)
ESMO PRECEPTORSHIP PROGRAMME
� While PDL1 results were awaited, he had rather rapid progression
� He was initiated on Nivolumab
� After first cycle, he was admitted with unexplained dyspnoea
� CT chest: no new findings
![Page 9: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/9.jpg)
ESMO PRECEPTORSHIP PROGRAMME
![Page 10: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/10.jpg)
ESMO PRECEPTORSHIP PROGRAMME
� He was found to be in CR after the 2nd cycle
� Presently he is in Q monthly Nivolumab 240 mg – completed 12 months
� He has left axillary LN, FNA proven adenocarcinoma as the only site of disease
� This lesion regresses after each dose of Nivolumab
� He had hyperthyroidism and later hypothyroidism and is on Thyroid hormone replacement
![Page 11: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/11.jpg)
ESMO PRECEPTORSHIP PROGRAMME
![Page 12: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/12.jpg)
ESMO PRECEPTORSHIP PROGRAMME
Questions
� How frequent is PDL1- 100% positive??
� This patient had rather rapid progression but still responded well to Nivolumab - !!!
� I f we give Nivolumab Q montly why not Q 2 monthly??
� What is the optimal dose of Nivolumab? Will low dose Nivolumab work ?
![Page 13: PD-L1 –100% : A rare entity · Dr Sanju Cyriac–Medical Oncologist, RajagiriHospital, India Immuno-oncology– Singapore – 26-27 November 2018. ESMO PRECEPTORSHIP PROGRAMME Disclosures:](https://reader033.vdocument.in/reader033/viewer/2022052019/6032cd23b9559d686c614796/html5/thumbnails/13.jpg)
ESMO Preceptorship Programme